Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $120

Benzinga · 2d ago
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $130 to $120.